Indikation und operative Verfahren bei MEN1-assoziierten duodenopankreatischen neuroendokrinen Neoplasien

Jerena Manoharan; Max Albers; Detlef K Bartsch

doi:10.1055/a-2103-3525

Zentralblatt für Chirurgie - Zeitschrift für Allgemeine, Viszeral-, Thorax- und Gefäßchirurgie, Table of Contents

Zentralbl Chir 2023; 148(06): 483-491
DOI: 10.1055/a-2103-3525

Übersicht

Indikation und operative Verfahren bei MEN1-assoziierten duodenopankreatischen neuroendokrinen Neoplasien

Indication and Surgical Procedures for MEN1-associated Duodenopancreatic Neuroendocrine Neoplasms

Jerena Manoharan

¹Klinik für Visceral-, Thorax- und Gefäßchirurgie, Universitätsklinikum Gießen und Marburg - Standort Marburg, Marburg, Deutschland (Ringgold ID: RIN61061)

,

Max Albers

¹Klinik für Visceral-, Thorax- und Gefäßchirurgie, Universitätsklinikum Gießen und Marburg - Standort Marburg, Marburg, Deutschland (Ringgold ID: RIN61061)

,

Detlef K Bartsch

¹Klinik für Visceral-, Thorax- und Gefäßchirurgie, Universitätsklinikum Gießen und Marburg - Standort Marburg, Marburg, Deutschland (Ringgold ID: RIN61061)

› Author Affiliations

Abstract

Zusammenfassung

Die optimale Therapie von duodenopankreatischen neuroendokrinen Neoplasien (dpNEN), die im Rahmen der multiplen endokrinen Neoplasie Typ 1 auftreten, stellt nach wie vor eine große Herausforderung dar und wird teilweise kontrovers diskutiert. Aufgrund der Rarität der Erkrankung fehlen prospektiv randomisierte Studien, sodass die meisten Empfehlungen bez. der Operationsindikation und des -verfahrens auf retrospektiven Fallserien basieren. Prinzipiell ist eine operative Therapie bei nicht funktionellen dpNEN > 2 cm, bei Malignitätsverdacht und bei funktionell aktiven dpNEN indiziert. Hierbei kommen eine Enukleation oder formale Pankreasresektionen mit oder ohne Lymphadenektomie in Betracht. Ziel der Therapie sollte es sein, hormonassoziierte Symptome zu beseitigen und einem aggressiven metastasierenden Verlauf vorzubeugen. Zugleich sollte bei den zumeist jungen Patienten die Pankreasfunktion und Lebensqualität durch möglichst parenchymsparende Resektionen erhalten werden.

Abstract

The optimal therapy of duodenopancreatic neuroendocrine neoplasia (dpNEN), which occurs in the context of multiple endocrine neoplasia type 1, is still a major challenge and is controversial. Due to the rarity of the disease, there is a lack of prospective randomised studies, so that most recommendations regarding the surgical indication and procedure are based on retrospective case series. In summary, surgical therapy is indicated for non-functional dpNEN > 2 cm, suspected malignancy and functionally active dpNEN. Enucleation or formal pancreatic resections with or without lymphadenectomy may be considered. The aim of therapy should be to eliminate hormone-associated symptoms and prevent an aggressive metastatic disease. At the same time, pancreatic function and quality of life should be preserved in the mostly young patients by resections that save as much parenchyma as possible.

Schlüsselwörter

endokrine Chirurgie - pankreatische neuroendokrine Neoplasien - Multiple endokrine Neoplasie Typ 1 - Insulinom - Gastrinom - nicht funktionelle pankreatische neuroendokrine Neoplasien

Keywords

endocrine surgery - multiple endocrine Neoplasie Type 1 - insulinoma - gastrinoma - duodenopancreatic neuroendocrine neoplasia

Full Text

References

Literatur
1 Falchetti A. Genetics of multiple endocrine neoplasia type 1 syndrome: what’s new and what’s old. F1000Research 2017; 6: F1000
2 Manoharan J, Raue F, Lopez CL. et al. Is Routine Screening of Young Asymptomatic MEN1 Patients Necessary?. World J Surg 2017; 41: 2026-2032
3 Chandrasekharappa SC, Guru SC, Manickam P. et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997; 276: 404-407
4 Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum Mutat 2008; 29: 22-32
5 Bartsch DK, Albers MB. Controversies in surgery for multiple endocrine neoplasia type 1-associated Zollinger-Ellison syndrome. Int J Endocrin Oncol 2015;
6 Kong W, Albers MB, Manoharan J. et al. Pancreaticoduodenectomy Is the Best Surgical Procedure for Zollinger-Ellison Syndrome Associated with Multiple Endocrine Neoplasia Type 1. Cancers (Basel) 2022; 14: 1928
7 Albers MB, Manoharan J, Bartsch DK. Hereditäre duodenopankreatische neuroendokrine Neoplasien. In: Kreis M, Bartsch DK, Lang H. Viszeral- und Allgemeinchirurgie. Springer Reference Medizin. Berlin, Heidelberg: Springer; 2022: 1-19
8 Goudet P, Murat A, Binquet C. et al. Risk factors and causes of death in MEN1 disease. A GTE (Groupe d’Etude des Tumeurs Endocrines) cohort study among 758 patients. World J Surg 2010; 34: 249-255
9 Brandi ML, Agarwal SK, Perrier ND. et al. Multiple Endocrine Neoplasia Type 1: Latest Insights. Endocr Rev 2021; 42: 133-170
10 Niederle B, Selberherr A, Bartsch DK. et al. Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome – An International Consensus Statement. Neuroendocrinology 2021; 111: 609-630
11 Klein Haneveld MJ, Van Treijen MJC, Pieterman CRC. et al. Initiating Pancreatic Neuroendocrine Tumor (pNET) Screening in Young MEN1 Patients: Results From the DutchMEN Study Group. J Clin Endocrinol Metab 2021; 106: 3515-3525
12 Thakker RV, Newey PJ, Walls GV. et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab 2012; 97: 2990-3011
13 de Laat JM, Pieterman CRC, Weijmans M. et al. Low accuracy of tumor markers for diagnosing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1 patients. J Clin Endocrinol Metab 2013; 98: 4143-4151
14 van Treijen MJC, van Beek DJ, van Leeuwaarde RS. et al. Diagnosing Nonfunctional Pancreatic NETs in MEN1: The Evidence Base. J Endocr Soc 2018; 2: 1067-1088
15 Bartsch DK, Slater EP, Albers M. et al. Higher risk of aggressive pancreatic neuroendocrine tumors in MEN1 patients with MEN1 mutations affecting the CHES1 interacting MENIN domain. J Clin Endocrinol Metab 2014; 99: E2387-E2391
16 Thevenon J, Bourredjem A, Faivre L. et al. Higher risk of death among MEN1 patients with mutations in the JunD interacting domain: a Groupe d’etude des Tumeurs Endocrines (GTE) cohort study. Hum Mol Genet 2013; 22: 1940-1948
17 Christakis I, Qiu W, Hyde SM. et al. Genotype-phenotype pancreatic neuroendocrine tumor relationship in multiple endocrine neoplasia type 1 patients: A 23-year experience at a single institution. Surgery 2018; 163: 212-217
18 Kouvaraki MA, Lee JE, Shapiro SE. et al. Genotype-phenotype analysis in multiple endocrine neoplasia type 1. Arch Surg 2002; 137: 641-647
19 Partelli S, Massironi S, Zerbi A. et al. Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: Interim analysis of prospective ASPEN trial. Br J Surg 2022; 109: 1186-1190
20 Partelli S, Tamburrino D, Lopez C. et al. Active Surveillance versus Surgery of Nonfunctioning Pancreatic Neuroendocrine Neoplasms ≤ 2 cm in MEN1 Patients. Neuroendocrinology 2016; 103: 779-786
21 Triponez F, Dosseh D, Goudet P. et al. Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg 2006; 243: 265-272
22 Triponez F, Goudet P, Dosseh D. et al. Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg 2006; 30: 654-662
23 Nell S, Verkooijen HM, Pieterman CRC. et al. Management of MEN1 Related Nonfunctioning Pancreatic NETs: A Shifting Paradigm: Results From the DutchMEN1 Study Group. Ann Surg 2018; 267: 1155-1160
24 Rinke A, Wiedenmann B, Auernhammer C. et al. S2k-Leitlinie Neuroendokrine Tumore. Z Gastroenterol 2018; 56: 583-681
25 Falconi M, Eriksson B, Kaltsas G. et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology 2016; 103: 153-171
26 Lévy-Bohbot N, Merle C, Goudet P. et al. Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry. Gastroenterol Clin Biol 2004; 28: 1075-1081
27 Vinault S, Mariet AS, Le Bras M. et al. Metastatic Potential and Survival of Duodenal and Pancreatic Tumors in Multiple Endocrine Neoplasia Type 1: A GTE and AFCE Cohort Study (Groupe d’étude des Tumeurs Endocrines and Association Francophone de Chirurgie Endocrinienne). Ann Surg 2020; 272: 1094-1101
28 Bartsch DK, Fendrich V, Langer P. et al. Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 2005; 242: 757-766
29 Lopez CL, Waldmann J, Fendrich V. et al. Long-term results of surgery for pancreatic neuroendocrine neoplasms in patients with MEN1. Langenbecks Arch Surg 2011; 396: 1187-1196
30 Hausman MS, Thompson NW, Gauger PG. et al. The surgical management of MEN-1 pancreatoduodenal neuroendocrine disease. Surgery 2004; 136: 1205-1211
31 Bartsch DK, Langer P, Wild A. et al. Pancreaticoduodenal endocrine tumors in multiple endocrine neoplasia type 1: surgery or surveillance?. Surgery 2000; 128: 958-966
32 Nell S, Borel Rinkes IHM, Verkooijen HM. et al. Early and Late Complications After Surgery for MEN1-related Nonfunctioning Pancreatic Neuroendocrine Tumors. Ann Surg 2018; 267: 352-356
33 Partelli S, Tamburrino D, Cherif R. et al. Risk and Predictors of Postoperative Morbidity and Mortality After Pancreaticoduodenectomy for Pancreatic Neuroendocrine Neoplasms: A Comparative Study With Pancreatic Ductal Adenocarcinoma. Pancreas 2019; 48: 504-509
34 Albers MB, Manoharan J, Bollmann C. et al. Results of Duodenopancreatic Reoperations in Multiple Endocrine Neoplasia Type 1. World J Surg 2019; 43: 552-558
35 Lopez CL, Albers MB, Bollmann C. et al. Minimally Invasive Versus Open Pancreatic Surgery in Patients with Multiple Endocrine Neoplasia Type 1. World J Surg 2016; 40: 1729-1736
36 van Beek DJ, Nell S, Vorselaars WMCM. et al. Complications After Major Surgery for Duodenopancreatic Neuroendocrine Tumors in Patients with MEN1: Results from a Nationwide Cohort. Ann Surg Oncol 2021; 28: 4387-4399
37 Ratnayake CBB, Loveday BP, Windsor JA. et al. Patient characteristics and clinical outcomes following initial surgical intervention for MEN1 associated pancreatic neuroendocrine tumours: A systematic review and exploratory meta-analysis of the literature. Pancreatology 2019; 19: 462-471
38 Fernández-Cruz L, Martínez I, Cesar-Borges G. et al. Laparoscopic Surgery in Patients With Sporadic and Multiple Insulinomas Associated With Multiple Endocrine Neoplasia Type 1. J Gastrointest Surg 2005; 9: 381-388
39 Anlauf M, Garbrecht N, Henopp T. et al. Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. World J Gastroenterol 2006; 12: 5440-5446
40 Lopez CL, Falconi M, Waldmann J. et al. Partial Pancreaticoduodenectomy Can Provide Cure for Duodenal Gastrinoma Associated With Multiple Endocrine Neoplasia Type 1. Ann Surg 2013; 257: 308-314
41 Thompson NW. Management of pancreatic endocrine tumors in patients with multiple endocrine neoplasia type 1. Surg Oncol Clin N Am 1998; 7: 881-891
42 MacFarlane MP, Fraker DL, Alexander HR. et al. Prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia type 1. Surgery 1995; 118: 973-979
43 Jensen RT, Niederle B, Mitry E. et al. Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006; 84: 173-182
44 Falconi M, Eriksson B, Kaltsas G. et al. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology 2016; 103: 153-171
45 Albers MB, Manoharan J, Bartsch DK. Contemporary surgical management of the Zollinger-Ellison syndrome in multiple endocrine neoplasia type 1. Best Pract Res Clin Endocrinol Metab 2019; 101318
46 Anlauf M, Perren A, Meyer CL. et al. Precursor lesions in patients with multiple endocrine neoplasia type 1-associated duodenal gastrinomas. Gastroenterology 2005; 128: 1187-1198
47 Norton JA, Alexander HR, Fraker DL. et al. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg 2001; 234: 495-505
48 Santucci N, Gaujoux S, Binquet C. et al. Pancreatoduodenectomy for Neuroendocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1: An AFCE (Association Francophone de Chirurgie Endocrinienne) and GTE (Groupe d’étude des Tumeurs Endocrines) Study. World J Surg 2021; 45: 1794-1802
49 Thompson NW. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med 1998; 243: 495-500
50 Mignon M, Cadiot G. Diagnostic and therapeutic criteria in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. J Intern Med 1998; 243: 489-494
51 Dickson PV, Rich TA, Xing Y. et al. Achieving eugastrinemia in MEN1 patients: both duodenal inspection and formal lymph node dissection are important. Surgery 2011; 150: 1143-1152
52 Stadil F, Bardram L, Gustafsen J. et al. Surgical treatment of the Zollinger-Ellison syndrome. World J Surg 1993; 17: 463-467
53 Tonelli F, Fratini G, Nesi G. et al. Pancreatectomy in multiple endocrine neoplasia type 1-related gastrinomas and pancreatic endocrine neoplasias. Ann Surg 2006; 244: 61-70
54 Imamura M, Komoto I, Ota S. et al. Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. World J Gastroenterol 2011; 17: 1343-1353
55 van Beek DJ, Nell S, Verkooijen HM. et al. Surgery for multiple endocrine neoplasia type 1-related insulinoma: long-term outcomes in a large international cohort. Br J Surg 2020; 107: 1489-1499
56 van Beek DJ, Nell S, Verkooijen HM. et al. Prognosis after surgery for multiple endocrine neoplasia type 1-related pancreatic neuroendocrine tumors: Functionality matters. Surgery 2021; 169: 963-973
57 Lopez-Egido J, Cunningham J, Berg M. et al. Menin’s interaction with glial fibrillary acidic protein and vimentin suggests a role for the intermediate filament network in regulating menin activity. Exp Cell Res 2002; 278: 175-183
58 Bartsch DK, Albers M, Knoop R. et al. Enucleation and limited pancreatic resection provide long-term cure for insulinoma in multiple endocrine neoplasia type 1. Neuroendocrinology 2013; 98: 290-298
59 Won JGS, Tseng HS, Yang AH. et al. Intra-arterial calcium stimulation test for detection of insulinomas: Detection rate, responses of pancreatic peptides, and its relationship to differentiation of tumor cells. Metabolism 2003; 52: 1320-1329
60 Lo CY, Chan FL, Tam SCF. et al. Value of intra-arterial calcium stimulated venous sampling for regionalization of pancreatic insulinomas. Surgery 2000; 128: 903-909
61 Sakurai A, Yamazaki M, Suzuki S. et al. Clinical features of insulinoma in patients with multiple endocrine neoplasia type 1: analysis of the database of the MEN Consortium of Japan. Endocr J 2012; 59: 859-866
62 Giudici F, Nesi G, Brandi ML. et al. Surgical management of insulinomas in multiple endocrine neoplasia type 1. Pancreas 2012; 41: 547-553
63 Eckhardt S, Schicker C, Maurer E. et al. Robotic-Assisted Approach Improves Vessel Preservation in Spleen-Preserving Distal Pancreatectomy. Dig Surg 2016; 33: 406-413
64 Albers MB, Almquist M, Bergenfelz A. et al. Complications of surgery for gastro-entero-pancreatic neuroendocrine neoplasias. Langenbeck’s Arch Surg 2020; 405: 137-143
65 Gauger PG, Doherty GM, Broome JT. et al. Completion pancreatectomy and duodenectomy for recurrent MEN-1 pancreaticoduodenal endocrine neoplasms. Surgery 2009; 146: 801-808
66 van Beek DJ, Takkenkamp TJ, Wong-Lun-Hing EM. et al. Risk factors for complications after surgery for pancreatic neuroendocrine tumors. Surgery 2022; 172: 127-136
67 Heeger K, Falconi M, Partelli S. et al. Increased rate of clinically relevant pancreatic fistula after deep enucleation of small pancreatic tumors. Langenbecks Arch Surg 2014; 399: 315-321
68 Brient C, Regenet N, Sulpice L. et al. Risk factors for postoperative pancreatic fistulization subsequent to enucleation. J Gastrointest Surg 2012; 16: 1883-1887
69 Lairmore TC, Chen VY, DeBenedetti MK. et al. Duodenopancreatic Resections in Patients With Multiple Endocrine Neoplasia Type 1. Ann Surg 2000; 231: 909
70 Pavel M, Baudin E, Couvelard A. et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95: 157-176
71 Sonoda A, Yamashita YI, Kondo T. et al. Clinicopathological features and menin expression of pancreatic neuroendocrine neoplasm associated with multiple endocrine neoplasia type 1. J Hepatobiliary Pancreat Sci 2020; 27: 984-991